Jeffrey C. Hanselman

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease

Anne C. Goldberg, Lawrence A. Leiter, Erik S.G. Stroes et al. · JAMA · 2019 · 478 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Christie M. Ballantyne, Maciej Banach, G.B. John Mancini et al. · Atherosclerosis · 2018 · 423 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

Stephen L. Pinkosky, Jeffrey C. Hanselman, Cheryl D. Bradshaw et al. · Journal of Lipid Research · 2012 · 236 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Inhibition of Sphingomyelin Synthesis Reduces Atherogenesis in Apolipoprotein E–Knockout Mice

Tae‐Sik Park, Robert L. Panek, Sandra Bak Mueller et al. · Circulation · 2004 · 222 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

María J. Gutiérrez, Noah L. Rosenberg, Diane MacDougall et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2014 · 172 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17